Medscape September 9, 2024
(Reuters) -Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early stage study, joining drugmakers vying for a share of the lucrative obesity treatment market and sending its shares up 27% on Monday.
The experimental treatment is part of the second generation of weight-loss drugs under development by companies including Pfizer and Roche, which aims to offer a more convenient alternative to injections.
Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The two companies are also developing oral weight-loss treatments, the market for which is expected to hit $150 billion by the early 2030s, according to some analysts.
“We’re very pleased with the totality of...
Today's Sponsors
Today's Sponsor